%0 Journal Article %T Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? %A Malapelle, Umberto %A Rossi, Antonio %A Bria, Emilio %J Journal of Thoracic Disease %D 2019 %B 2019 %9 %! Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing? %K %X Non-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al . demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor ( EGFR ) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs) (2). %U https://jtd.amegroups.org/article/view/31260 %P S1837-S1840 %@ 2077-6624